Hafion, Inc. is a vaccine company focusing on developing broadly protective prophylactic and therapeutic vaccines against bacterial pathogens through a novel platform technology. Its current focus is combating Gram-negative bacterial infections, particularly targeting Pseudomonas aeruginosa (Pa). The market for Pa vaccines is significant due to the high incidence of infections, especially among cystic fibrosis patients and those with compromised immune systems. Despite the unmet need, no approved prophylactic or therapeutic vaccines exist for Pa, presenting a substantial opportunity.
Hafion's proprietary T3SA Vaccine Technology addresses this gap by targeting highly conserved components of the Type 3 Secretion Apparatus (T3SA) of Gram-negative bacteria. Its lead candidate, HAF-101, demonstrates broad serotype-independent protection by inducing systemic and mucosal immunity. Delivered intranasally, this needle-free approach enhances patient compliance. Proof-of-concept studies have demonstrated the safety, immunogenicity, and protective efficacy of HAF-101 in multiple animal models. Key achievements include significantly reducing bacterial colonization in mice, cystic fibrosis rats, and rabbits, as well as protection against lethal Pa challenges in rabbit models. The vaccine's final nanoemulsion formulation has been optimized for intranasal delivery, combining fusion protein antigens from the T3SA platform and the mucosal adjuvant LTA1 to elicit robust immune responses.
The company's competitive advantages include broad-spectrum protection with serotype-independent immunity, robust systemic and mucosal responses, significant reduction in bacterial colonization, intranasal delivery, and a proprietary formulation that is expandable to other pathogens. These features position Hafion as a leader in the next generation of bacterial vaccines. Over $2.5 million in non-dilutive funding has been secured to date, with the company now seeking up to $5 million in seed funding
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.hafion.com
- Keywords
- Dublin.
Hafion, Inc. Questions
Hafion, Inc.'s website is http://www.hafion.com
Hafion, Inc.'s LinkedIn profile is https://www.linkedin.com/company/hafion-inc
Hafion, Inc.'s industry is
Biotechnology Research
Hafion, Inc.'s top competitors are
Bio-Angle Vacs,
Scotia Biologics,
Gylden Pharma,
Id-Antigens,
Precivax Therapeutics,
Gennova Biopharmaceuticals,
Bactivax Itn,
Althost Consortium,
Biocina,
Bactivac.
Hafion, Inc.'s categories are Biotechnology Research
Hafion, Inc.'s founding year is 2016
